Pharma forum ends, now industry wants action
This article was originally published in Scrip
EU member states should give pharmaceutical companies clear guidance on the evidence that will be needed to secure an appropriate reward for innovative drugs. Industry should have a role in providing drug information to patients. And the authorities should adhere to a set of good practices in assessing relative effectiveness.
You may also be interested in...
Coronavirus Update: Setback With Hydroxychloroquine, Slowdown In UK ADR Reports, But Novel Drugs Begin Trials
In addition to our daily in-depth coverage of key events relating to the coronavirus, we’re bringing you a periodic round-up of other pandemic developments. This edition covers events at the national, European and global level.
Participants in a recent webinar looked at how the coronavirus is changing the way we look at clinical trials and whether new EU COVID-19 guidance might hold lessons for future approaches to study design.
There is much talk around the importance of clinical trials in finding new treatments and vaccines for COVID-19 patients, but observational studies in clinical practice also have a vital role to play, including the impact on pregnant women.